CARLSBAD, Calif.–(BUSINESS WIRE)–Arima Genomics, Inc., a cancer diagnostics company bringing DNA sequence and structure together to advance cancer therapy selection, today announced new data to be presented at the Association for Molecular Pathology (AMP) 2026 Europe Congress, taking place June 15–17, 2026, in Tallinn, Estonia. The new findings demonstrate that Arima’s Hi-C sequencing-based approach, available clinically through the Aventa™ Lymphoma test, identified clinically relevant lympho
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
